Home2019-04-11T17:03:44+00:00

We all have people close to us who have been affected by a neurodegenerative disease.

Amylyx is developing AMX0035 to improve the lives of people living with ALS, Alzheimer’s and other diseases of the brain.

Learn More

Areas of Focus

Centaur ALS Trial

April 03, 2019

Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial

Wave

Amylyx Pharmaceuticals, Inc., in collaboration with the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation (ADDF) and the Cure Alzheimer’s Fund, today announced the dosing of its first patients in a recently expanded Phase 2 clinical trial (PEGASUS) to assess AMX0035 in individuals with Alzheimer’s disease.

Read More

October 24, 2017

Innovative Alzheimer’s Disease Combination Therapy Trial Supported By New Joint Funding Initiative

Wave

The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation (ADDF) are collaborating to jointly fund a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.

Read More

September 19, 2017

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of ALS

Wave

Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis (ALS).

Read More

Contact Us